JP2005533517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533517A5 JP2005533517A5 JP2004524748A JP2004524748A JP2005533517A5 JP 2005533517 A5 JP2005533517 A5 JP 2005533517A5 JP 2004524748 A JP2004524748 A JP 2004524748A JP 2004524748 A JP2004524748 A JP 2004524748A JP 2005533517 A5 JP2005533517 A5 JP 2005533517A5
- Authority
- JP
- Japan
- Prior art keywords
- sirna
- virus
- modified
- pharmaceutical composition
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004459 Small interfering RNA Proteins 0.000 claims 65
- 239000004055 small Interfering RNA Substances 0.000 claims 65
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 241000711549 Hepacivirus C Species 0.000 claims 26
- 238000012986 modification Methods 0.000 claims 23
- 125000003729 nucleotide group Chemical group 0.000 claims 22
- 241000700605 Viruses Species 0.000 claims 16
- 239000002773 nucleotide Substances 0.000 claims 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 14
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 11
- 125000002652 ribonucleotide group Chemical group 0.000 claims 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 9
- -1 fluoro- Chemical class 0.000 claims 9
- 230000004048 modification Effects 0.000 claims 9
- 108091028664 Ribonucleotide Proteins 0.000 claims 8
- 239000002336 ribonucleotide Substances 0.000 claims 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 241000991587 Enterovirus C Species 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 241000712461 unidentified influenza virus Species 0.000 claims 5
- 241000711573 Coronaviridae Species 0.000 claims 4
- 241001115402 Ebolavirus Species 0.000 claims 4
- 241000700721 Hepatitis B virus Species 0.000 claims 4
- 241000724675 Hepatitis E virus Species 0.000 claims 4
- 208000037262 Hepatitis delta Diseases 0.000 claims 4
- 241000724709 Hepatitis delta virus Species 0.000 claims 4
- 241000709721 Hepatovirus A Species 0.000 claims 4
- 241000282414 Homo sapiens Species 0.000 claims 4
- 241000351643 Metapneumovirus Species 0.000 claims 4
- 241000702263 Reovirus sp. Species 0.000 claims 4
- 241000702670 Rotavirus Species 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 208000003154 papilloma Diseases 0.000 claims 4
- 230000010076 replication Effects 0.000 claims 4
- 241001430294 unidentified retrovirus Species 0.000 claims 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 3
- 229940104302 cytosine Drugs 0.000 claims 3
- 230000009368 gene silencing by RNA Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229940035893 uracil Drugs 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 2
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 2
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims 2
- 108091036066 Three prime untranslated region Proteins 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108010083644 Ribonucleases Proteins 0.000 claims 1
- 102000006382 Ribonucleases Human genes 0.000 claims 1
- 108091081021 Sense strand Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 102000051308 human DICER1 Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39860502P | 2002-07-26 | 2002-07-26 | |
| US60/398,605 | 2002-07-26 | ||
| US46183803P | 2003-04-11 | 2003-04-11 | |
| US60/461,838 | 2003-04-11 | ||
| US47023003P | 2003-05-14 | 2003-05-14 | |
| US60/470,230 | 2003-05-14 | ||
| PCT/US2003/023104 WO2004011647A1 (en) | 2002-07-26 | 2003-07-25 | Modified small interfering rna molecules and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006165652A Division JP4718379B2 (ja) | 2002-07-26 | 2006-06-15 | 修飾された低分子干渉ｒｎａ分子および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005533517A JP2005533517A (ja) | 2005-11-10 |
| JP2005533517A5 true JP2005533517A5 (https=) | 2006-08-03 |
| JP4709545B2 JP4709545B2 (ja) | 2011-06-22 |
Family
ID=32397947
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004524748A Expired - Fee Related JP4709545B2 (ja) | 2002-07-26 | 2003-07-25 | 修飾された低分子干渉ｒｎａ分子および使用方法 |
| JP2006165652A Expired - Fee Related JP4718379B2 (ja) | 2002-07-26 | 2006-06-15 | 修飾された低分子干渉ｒｎａ分子および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006165652A Expired - Fee Related JP4718379B2 (ja) | 2002-07-26 | 2006-06-15 | 修飾された低分子干渉ｒｎａ分子および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20050058982A1 (https=) |
| EP (1) | EP1532248B1 (https=) |
| JP (2) | JP4709545B2 (https=) |
| AT (1) | ATE427352T1 (https=) |
| AU (1) | AU2003261231A1 (https=) |
| CA (2) | CA2884658A1 (https=) |
| DE (1) | DE60326961D1 (https=) |
| ES (1) | ES2322145T3 (https=) |
| WO (1) | WO2004011647A1 (https=) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| ATE556714T1 (de) | 2002-02-01 | 2012-05-15 | Life Technologies Corp | Doppelsträngige oligonukleotide |
| EP1572902B1 (en) * | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| AU2003219817B2 (en) * | 2002-02-20 | 2006-08-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis C virus |
| US20090192105A1 (en) * | 2002-02-20 | 2009-07-30 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA) |
| US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
| GB2406169B (en) * | 2002-06-12 | 2006-11-01 | Ambion Inc | Methods and compositions relating to labeled rna molecules that reduce gene expression |
| US20100075423A1 (en) * | 2002-06-12 | 2010-03-25 | Life Technologies Corporation | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
| AU2003261231A1 (en) | 2002-07-26 | 2004-02-16 | Chiron Corporation | Modified small interfering rna molecules and methods of use |
| US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| US20060160759A1 (en) * | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
| DE10302421A1 (de) * | 2003-01-21 | 2004-07-29 | Ribopharma Ag | Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit |
| WO2004092383A2 (en) * | 2003-04-15 | 2004-10-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| AU2004263830B2 (en) | 2003-06-13 | 2008-12-18 | Alnylam Pharmaceuticals, Inc. | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| US20050043266A1 (en) * | 2003-07-25 | 2005-02-24 | Sumedha Jayasena | Short interfering RNA as an antiviral agent for hepatitis C |
| WO2005040388A2 (en) * | 2003-08-22 | 2005-05-06 | Nucleonics Inc. | Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments |
| US20050060771A1 (en) * | 2003-09-11 | 2005-03-17 | Farmer Andrew Alan | siRNA encoding constructs and methods for using the same |
| US7371802B2 (en) * | 2003-10-28 | 2008-05-13 | Basell Poliolefine Italia S.R.L. | Components and catalysts for the polymerization of olefins |
| CA2558771C (en) | 2004-03-05 | 2013-01-08 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of rnai agents |
| CA2559955C (en) * | 2004-03-15 | 2016-02-16 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
| WO2005111219A1 (en) * | 2004-04-16 | 2005-11-24 | University Of Washington | METHODS AND VECTORS FOR EXPRESSING siRNA |
| US20060014289A1 (en) * | 2004-04-20 | 2006-01-19 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
| AU2005247509C1 (en) * | 2004-05-27 | 2012-09-20 | Alnylam Pharmaceuticals, Inc. | Nuclease resistant double-stranded ribonucleic acid |
| US7297786B2 (en) | 2004-07-09 | 2007-11-20 | University Of Iowa Research Foundation | RNA interference in respiratory epitheial cells |
| US8361976B2 (en) | 2004-07-09 | 2013-01-29 | University Of Massachusetts | Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules |
| EP1791567B1 (en) | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| DE602005027479D1 (de) | 2004-09-24 | 2011-05-26 | Alnylam Pharmaceuticals Inc | Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| WO2006039656A2 (en) * | 2004-10-01 | 2006-04-13 | Novartis Vaccines And Diagnostics Inc. | Modified small interfering rna molecules and methods of use |
| CA2587493A1 (en) * | 2004-11-30 | 2006-06-08 | Aeras Global Tb Vaccine Foundation | Bacterial packaging strains usefuel for generation and production of recombinant double-stranded rna nucleocapsids and uses thereof |
| US20060142228A1 (en) * | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
| NZ560936A (en) * | 2005-02-03 | 2010-04-30 | Benitec Inc | RNAI expression constructs |
| CN1313159C (zh) * | 2005-06-03 | 2007-05-02 | 陈志南 | HAb18G/CD147分子小片段干涉RNA药物及其用途 |
| WO2007053696A2 (en) * | 2005-11-01 | 2007-05-10 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
| EP2905336A1 (en) | 2007-03-29 | 2015-08-12 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the ebola |
| CN101686939B (zh) * | 2007-04-17 | 2013-03-27 | 巴克斯特国际公司 | 用于肺部投送的核酸微粒 |
| AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| WO2009008645A2 (en) * | 2007-07-06 | 2009-01-15 | Mogam Biotechnology Research Institute | Linear double-stranded rna molecule interfering with different target genes |
| EP2195428B1 (en) | 2007-09-19 | 2013-12-11 | Applied Biosystems, LLC | SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| KR101070654B1 (ko) | 2008-06-11 | 2011-10-07 | 건국대학교 산학협력단 | 중증급성호흡기증후군 코로나바이러스(ｓｃｖ)에 대한 저해활성을 가지는 조성물 |
| JP2011190176A (ja) * | 2008-07-07 | 2011-09-29 | Kyowa Hakko Kirin Co Ltd | 肥満細胞の脱顆粒抑制剤 |
| RU2011132045A (ru) * | 2008-12-31 | 2013-02-10 | Эбботт Лэборетриз | Праймеры и зонды для детектирования вируса гепатита с |
| WO2010105372A1 (en) * | 2009-03-20 | 2010-09-23 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis c virus expression |
| JPWO2010137570A1 (ja) * | 2009-05-29 | 2012-11-15 | 学校法人慶應義塾 | 抗ウイルス剤または抗癌剤 |
| US8435961B2 (en) * | 2009-06-26 | 2013-05-07 | Massachusetts Institute Of Technology | Methods and compositions for increasing the activity of inhibitory RNA |
| US8268550B2 (en) * | 2009-06-26 | 2012-09-18 | Massachusetts Institute Of Technology | Compositions and methods for identification of PARP function, inhibitors, and activators |
| WO2010151664A2 (en) | 2009-06-26 | 2010-12-29 | Massachusetts Institute Of Technology | Compositions and methods for treating cancer and modulating stress granule formation |
| WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| AP2015008874A0 (en) | 2009-08-14 | 2015-11-30 | Alnylam Pharmaceuticals Inc | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
| PL2563920T3 (pl) | 2010-04-29 | 2017-08-31 | Ionis Pharmaceuticals, Inc. | Modulacja ekspresji transtyretyny |
| US9029341B2 (en) * | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| US8217163B2 (en) * | 2010-09-20 | 2012-07-10 | Biomics Biotechnologies Co., Ltd. | Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas |
| EP2817287B1 (en) | 2012-02-24 | 2018-10-03 | Arbutus Biopharma Corporation | Trialkyl cationic lipids and methods of use thereof |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| KR101520383B1 (ko) | 2012-08-02 | 2015-05-15 | 에이비온 주식회사 | Ｈｐｖ 감염과 관련된 암의 치료용 조성물 |
| US9840703B2 (en) | 2013-01-11 | 2017-12-12 | Children's Medical Center Corporation | Methods and compositions for the production of siRNAs |
| AU2014340149B2 (en) | 2013-10-22 | 2020-12-24 | Shire Human Genetic Therapies, Inc. | CNS delivery of mRNA and uses thereof |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| JP6767976B2 (ja) | 2014-12-05 | 2020-10-14 | トランスレイト バイオ， インコーポレイテッド | 関節疾患の治療のためのメッセンジャーｒｎａ治療法 |
| WO2016149508A1 (en) | 2015-03-19 | 2016-09-22 | Shire Human Genetic Therapies, Inc. | Mrna therapy for pompe disease |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2016183366A2 (en) * | 2015-05-12 | 2016-11-17 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing expression of hepatitis d virus rna |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| EP3556764A4 (en) | 2016-12-16 | 2021-01-06 | Gifu University | NUCLEOSIDE DERIVATIVE AND USE FOR IT |
| TN2019000308A1 (en) | 2017-07-06 | 2021-05-07 | Arrowhead Pharmaceuticals Inc | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE |
| JP7173467B2 (ja) | 2017-10-31 | 2022-11-16 | ヤマサ醤油株式会社 | ヌクレオシド誘導体及びその利用 |
| US20230144739A1 (en) * | 2020-03-16 | 2023-05-11 | Medesis Pharma | Treatment of covid-19 with reverse micelle system comprising unmodified oligonucleotides |
| EP4121018A4 (en) | 2020-03-17 | 2024-07-03 | Genevant Sciences Gmbh | CATIONIC LIPIDS FOR LIPID DNANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLA CELLS |
| CN115884796A (zh) * | 2020-03-18 | 2023-03-31 | 南京强新生物医药有限公司 | 靶向冠状病毒基因的基因沉默剂及其用途 |
| WO2021226479A1 (en) * | 2020-05-07 | 2021-11-11 | The Regents Of The University Of California | Inhaled statins for treatment of viral respiratory diseases |
| AU2021403156A1 (en) | 2020-12-18 | 2023-07-13 | Genevant Sciences Gmbh | Peg lipids and lipid nanoparticles |
| KR20240146674A (ko) | 2022-01-31 | 2024-10-08 | 제네반트 사이언시즈 게엠베하 | 지질 나노입자를 위한 이온화 가능한 양이온성 지질 |
| AU2023255614A1 (en) | 2022-04-18 | 2024-10-24 | Vertex Pharmaceuticals Incorporated | Compositions and methods for enhancing aav therapy and decreasing tropism of aav to the liver. |
| GB202208347D0 (en) | 2022-06-07 | 2022-07-20 | Univ Court Univ Of Glasgow | Targets for cancer therapy |
| AU2023408479A1 (en) | 2022-12-19 | 2025-05-01 | Arnatar Therapeutics, Inc | Advanced rna targeting (arnatar) |
| EP4562158A1 (en) | 2023-06-13 | 2025-06-04 | Arnatar Therapeutics, Inc | Advanced rna targeting (arnatar) for angiotensinogen |
| WO2025052278A1 (en) | 2023-09-05 | 2025-03-13 | Genevant Sciences Gmbh | Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells |
| WO2025133951A1 (en) | 2023-12-21 | 2025-06-26 | Genevant Sciences Gmbh | Ionizable lipids suitable for lipid nanoparticles |
| WO2025165891A1 (en) | 2024-01-29 | 2025-08-07 | Arnatar Therapeutics, Inc | Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof |
| EP4671372A3 (en) | 2024-01-29 | 2026-03-11 | Arnatar Therapeutics, Inc | Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof |
| WO2026022656A2 (en) | 2024-07-22 | 2026-01-29 | Genevant Sciences Gmbh | Lipid particle formulations with permanently charged cationic lipids |
| WO2026022677A1 (en) | 2024-07-22 | 2026-01-29 | Genevant Sciences Gmbh | Permanently charged cationic lipids |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190864B1 (en) * | 1991-05-08 | 2001-02-20 | Chiron Corporation | HCV genomic sequences for diagnostics and therapeutics |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| US5610054A (en) * | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US6174868B1 (en) * | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| US5922857A (en) | 1992-09-28 | 1999-07-13 | Chiron Corporation | Methods and compositions for controlling translation of HCV proteins |
| US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| WO1995030746A1 (en) * | 1994-05-10 | 1995-11-16 | The General Hospital Corporation | Antisense inhibition of hepatitis c virus |
| US6107027A (en) * | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
| US5874565A (en) * | 1995-08-29 | 1999-02-23 | Washington University | Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus |
| NZ507848A (en) | 1996-10-28 | 2005-01-28 | Univ Washington | Method of increasing the mutation rate of a virus in a non-human by administering an RNA nucleoside analogue to a virally infected cell |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US20020155582A1 (en) * | 1999-12-23 | 2002-10-24 | Lemon Stanley M. | Replication competent hepatitis C virus and methods of use |
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| KR20030005197A (ko) | 2000-02-18 | 2003-01-17 | 샤이어 바이오켐 인코포레이티드 | 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법 |
| ES2336887T5 (es) * | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| WO2002032920A2 (en) | 2000-10-18 | 2002-04-25 | Pharmasset Limited | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| SK286630B6 (sk) * | 2001-01-22 | 2009-02-05 | Merck & Co., Inc. | Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
| EP1383782A1 (en) * | 2001-03-26 | 2004-01-28 | Sirna Therpeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| US20050209180A1 (en) * | 2001-05-18 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| DK2280070T3 (en) * | 2001-07-23 | 2015-08-24 | Univ Leland Stanford Junior | Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals |
| US20030219823A1 (en) * | 2001-09-07 | 2003-11-27 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| AU2003219817B2 (en) * | 2002-02-20 | 2006-08-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis C virus |
| AU2003261231A1 (en) | 2002-07-26 | 2004-02-16 | Chiron Corporation | Modified small interfering rna molecules and methods of use |
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| DE10302421A1 (de) | 2003-01-21 | 2004-07-29 | Ribopharma Ag | Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit |
| US20050043266A1 (en) * | 2003-07-25 | 2005-02-24 | Sumedha Jayasena | Short interfering RNA as an antiviral agent for hepatitis C |
| WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| AR052918A1 (es) * | 2005-02-25 | 2007-04-11 | Recordati Ireland Ltd | Clorhidrato de lercanidipina amorfo |
| AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| EP3000885B1 (en) * | 2009-12-18 | 2018-07-25 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
-
2003
- 2003-07-25 AU AU2003261231A patent/AU2003261231A1/en not_active Abandoned
- 2003-07-25 EP EP20030771767 patent/EP1532248B1/en not_active Expired - Lifetime
- 2003-07-25 CA CA 2884658 patent/CA2884658A1/en not_active Abandoned
- 2003-07-25 WO PCT/US2003/023104 patent/WO2004011647A1/en not_active Ceased
- 2003-07-25 JP JP2004524748A patent/JP4709545B2/ja not_active Expired - Fee Related
- 2003-07-25 ES ES03771767T patent/ES2322145T3/es not_active Expired - Lifetime
- 2003-07-25 DE DE60326961T patent/DE60326961D1/de not_active Expired - Lifetime
- 2003-07-25 US US10/626,879 patent/US20050058982A1/en not_active Abandoned
- 2003-07-25 CA CA2493949A patent/CA2493949C/en not_active Expired - Fee Related
- 2003-07-25 AT AT03771767T patent/ATE427352T1/de not_active IP Right Cessation
-
2006
- 2006-06-15 JP JP2006165652A patent/JP4718379B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-30 US US13/075,944 patent/US20120122962A1/en not_active Abandoned
-
2013
- 2013-03-12 US US13/796,606 patent/US9139833B2/en not_active Expired - Fee Related
-
2015
- 2015-08-06 US US14/819,606 patent/US20150361432A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533517A5 (https=) | ||
| JP7506670B2 (ja) | 脂質ナノ粒子製剤 | |
| CN101603042B (zh) | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 | |
| CN113286882A (zh) | 脂质纳米颗粒制剂 | |
| JP2012105686A5 (https=) | ||
| Ebert et al. | 5′ Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice | |
| CA2493949A1 (en) | Modified small interfering rna molecules and methods of use | |
| JP2008526876A5 (https=) | ||
| AU2009202763A1 (en) | Double-stranded nucleic acid | |
| JP2016526018A5 (https=) | ||
| Schaar et al. | Anti-adenoviral artificial MicroRNAs expressed from AAV9 vectors inhibit human adenovirus infection in immunosuppressed Syrian hamsters | |
| Deng et al. | The highly conserved 5'untranslated region as an effective target towards the inhibition of Enterovirus 71 replication by unmodified and appropriate 2'-modified siRNAs | |
| CN103275971A (zh) | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 | |
| JP4545091B2 (ja) | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 | |
| Teng et al. | Can G-quadruplex become a promising target in HBV therapy? | |
| JP2006523103A5 (https=) | ||
| Blazquez et al. | U1 interference (U1i) for antiviral approaches | |
| Johnson et al. | Effect of mutations in the mouse hepatitis virus 3′(+) 42 protein binding element on RNA replication | |
| KR101218470B1 (ko) | Ｈｃｖ 감염 세포에서 특이적으로 마이크로 ｒｎａ에 대한 안티센스를 방출하는 엡타자임 및 이를 이용한 ｈｃｖ 관련 질환 치료용 조성물 | |
| US8957199B2 (en) | Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus | |
| Mao et al. | Inhibition of hepatitis C virus by an M1GS ribozyme derived from the catalytic RNA subunit of Escherichia coli RNase P | |
| de Carvalho et al. | Multi-targeted gene silencing strategies inhibit replication of Canine morbillivirus | |
| JP4228071B2 (ja) | Ｃ型肝炎ウイルスのタンパク質合成及び／又はｃ型肝炎ウイルスの複製を抑制することができる二本鎖オリゴヌクレオチド | |
| Barik | Treating respiratory viral diseases with chemically modified, second generation intranasal siRNAs | |
| US9068160B2 (en) | Methods of producing an antisense viral particle population |